All-Oral 12-Week Combination Treatment With Daclatasvir and Sofosbuvir in Patients Infected With HCV Genotype 3: ALLY-3 Phase 3 Study

Reported By Jules Levin

AASLD 2014 Boston Nov 7-11

Nelson DR,1 Cooper JN,2 Lalezari JP,3 Lawitz E,4 Pockros P,5 Freilich BF,6 Younes ZH,7Harlan W,8 Ghalib R,9Oguchi G,10 Thuluvath P,11 Ortiz-Lasanta G,12 Rabinovitz M,13 Bernstein D,14 Bennett M,15 Hawkins T,16 Ravendhran N,17 Sheikh AM,18 Varunok P,19 Kowdley KV,20 Hennicken D,21 McPhee F,21 Rana K,21 and Hughes EA21 on behalf of the ALLY-3 Study Team

1University of Florida, Gainesville, FL; 2Inova Fairfax Hospital, Falls Church, VA; 3Quest Clinical Research, San Francisco, CA; 4Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX; 5Scripps Clinic, La Jolla, CA; 6Kansas City Research Institute, Kansas City, MO; 7Gastro One, Germantown, TN; 8Asheville Gastroenterology Associates, Asheville, NC;

9Texas Clinical Research Institute, Arlington, TX; 10Midland Florida Clinical Research Center, DeLand, FL; 11Mercy Medical Center, Baltimore, MD; 12Fundación de Investigación de Diego, Santurce, Puerto Rico; 13University of Pittsburgh, Pittsburgh, PA; 14Hofstra North Shore-Long Island Jewish School of Medicine, Manhasset, NY; 15Medical Associates Research Group, San Diego, CA; 16Southwest CARE Center, Santa Fe, NM; 17Digestive Disease Associates, Baltimore, MD; 18Gastrointestinal Specialists of Georgia, Marietta, GA; 19Premier Medical Group of Hudson Valley, Poughkeepsie, NY; 20Swedish Medical Center, Seattle, WA; 21Bristol-Myers Squibb Research and Development, Princeton, NJ